Document Detail

A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
MedLine Citation:
PMID:  7474300     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to compare the effects of a novel modified tissue-type plasminogen activator (t-PA), E6010, to those of native t-PA and urokinase on reperfusion arrhythmias (premature ventricular complexes: PVC) and the mortality rate after coronary thrombolysis. The frequency of PVC and the mortality rate were evaluated in anesthetized dogs which had 1-, 3- or 6-h-old thrombi induced by a copper coil in the coronary artery. Thrombolytic treatment with a bolus intravenous (iv) injection of E6010 was compared with the continuous iv administration of native t-PA or urokinase. The frequency of PVC was significantly lower in the E6010 group than in the native t-PA and urokinase groups (P < 0.05). The mortality rate in the E6010 group (0.0%) tended to be lower than those in the native t-PA group (10.7%) and the urokinase group (7.1%). These results indicate that the bolus iv injection of E6010 reduced both PVC and the mortality rate, compared with the continuous iv administration of native t-PA or urokinase for coronary thrombolysis; Therefore, E6010 may have beneficial effects in prehospital thrombolysis.
M Saito; S Suzuki; Y Yui; C Kawai
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Japanese circulation journal     Volume:  59     ISSN:  0047-1828     ISO Abbreviation:  Jpn. Circ. J.     Publication Date:  1995 Aug 
Date Detail:
Created Date:  1995-12-04     Completed Date:  1995-12-04     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7806868     Medline TA:  Jpn Circ J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  556-64     Citation Subset:  IM    
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Chi-Square Distribution
Coronary Thrombosis / mortality,  therapy*
Epidermal Growth Factor / therapeutic use*
Fibrinolytic Agents / therapeutic use*
Myocardial Reperfusion Injury / prevention & control*
Plasminogen Activators / therapeutic use*
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Urokinase-Type Plasminogen Activator / therapeutic use*
Ventricular Premature Complexes / etiology,  prevention & control*
Reg. No./Substance:
0/Fibrinolytic Agents; 122007-85-6/E 6010; 62229-50-9/Epidermal Growth Factor; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determinants of exercise capacity in the hypertensive elderly--a study based on the assessment of ca...
Next Document:  Effects of suprachiasmatic lesions on circadian rhythms of blood pressure, heart rate and locomotor ...